Pharmaceuticals And Biotech Are A Hot Space For Activists Right NowGuest Post
Since it has been a relatively quiet week – for proxy season, at least – I want to provide a little bit more insight into one of our two feature articles from the April issue.
It’s something of an irony that just as Bill Ackman decides to get out of Valeant Pharmaceuticals International, the rest of the activist community appears to be refocusing on the sector. Perhaps it’s a function of real estate faltering a little or oil prices failing to stabilize (though the outlook is better than it was a while ago). Perhaps it has . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.